Insulin analogues choose a new sugar

Posted by Greyhill on November 20, 2008 in Diabetes

Novo Nordisk in the July 17, 2007 in Beijing held a “Connaught and Rui-Rui %26 Connaught and 30 cartridge will be listed” will meet the media. Chinese Medical Association diabetes credits will be chairman of the Sino-Japanese Friendship Hospital Director Professor Yang Wenying Endocrinology at the meeting on the status quo at home and abroad diabetes and insulin analogues on the application in detail and Connaught and Rui-Rui %26 Connaught and 30 cartridge In diabetes treatment given to the important role of a fully affirmed.

According to experts, in order to enable patients with diabetes use insulin for effective diabetes treatment, in order to better control blood sugar, reduce the incidence of low blood sugar and insulin injections people bid farewell to 30 minutes before they can eat it is not convenient, Novo Nordisk listed in China Connaught and the insulin analogue Connaught and Rui-Rui %26 30 cartridge. The listing of the Connaught and Rui-Rui %26 Connaught and 30 cartridges can be easily China’s original use of more than 100 million Connaught and T 3 of diabetes patients with blood sugar control, so that they do not have to bid farewell to the hands of the T-shaped syringe can understand that insulin analogue The treatment of life brought about by the changes and save the patients with drug costs, more economical to use more convenient.

As China’s economic development, the number of diabetic patients have shown rapid growth, according to the Ministry of Health survey found that patients with diabetes in China every day add about 3,000 cases, each of approximately 1.2 million cases of diabetes patients. “The Economist” this year, the Ministry of Information in the June 13 release of a report entitled “developed and developing countries, the economic cost of diabetes,” the latest research report, wantonly spread of diabetes in developed and developing countries is becoming a heavy Financial burden. In China, only cost a loss of productivity on the GDP accounted for 0.6 percent. Clearly, we are brought about by the loss of diabetes at great cost.

For many patients with diabetes speaking, good blood glucose control is the key to stable condition. Adverse long-term blood sugar control will accelerate the occurrence of complications and development of the body have a serious health threat to patients and their families and bring a heavy financial burden. For those who do not target the patients blood sugar, experts recommend starting treatment in the early stages of use of insulin analogues, in order to avoid complications of diabetes patients bring physical injury and economic burden.

At present, with the idea of the update, the success of new development of insulin, insulin analogues in the treatment of diabetes in the target of increasing attention. Now, on a global scale use of insulin analogues of patients has reached 3 million, insulin analogue market has accounted for the overall insulin market of nearly 50 percent, insulin analogue for diabetes is becoming a new field of choice. The development of insulin analogues, the treatment of diabetes is a major progress, the use of more flexible and comprehensive control of blood sugar, while reducing the risk of low blood sugar. Insulin analogues through the adjustment of the local chemical structure of insulin to make it injectiononset time and the role of human and natural characteristics of insulin secretion even more similar, so that more safe and effective treatment of insulin.

Novo Nordisk from the production of insulin analogues Connaught and Rui-Rui 30 %26 Connaught and better able to simulate physiological insulin secretion, to improve postprandial glucose control and better able to achieve HbA1c control objectives, reduce night-time low Blood sugar risk for diabetes is more science more effective treatments.